Lumos Pharma News

Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024

AUSTIN, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report first quarter 2024 financial

GlobeNewswireMay 10 02:51

Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings

Lumos Pharma, Inc. (NASDAQ:LUMO) announced today that abstracts reviewing data from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials will be presented at several upcoming medical meetings in the US and Europe.

GlobeNewswireApr 19 04:05

Lumos Pharma's LUM-201 Receives 'Buy' Rating on Strong Market Position and Promising Trial Outcomes

TipRanksMar 20 23:45

Lumos Pharma Announces USPTO Has Granted Patent Protection For Novel Formulation Of LUM-201, Extending Exclusivity To 2042

Lumos Pharma Announces USPTO Has Granted Patent Protection For Novel Formulation Of LUM-201, Extending Exclusivity To 2042

BenzingaMar 20 20:06

Lumos Pharma Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

Yahoo FinanceMar 10 20:31

Analysts Are Bullish on Top Healthcare Stocks: Lumos Pharma (LUMO), Arcturus Therapeutics (ARCT)

TipRanksMar 8 19:30

Earnings Call Summary | Lumos Pharma(LUMO.US) Q4 2023 Earnings Conference

The following is a summary of the Lumos Pharma, Inc. (LUMO) Q4 2023 Earnings Call Transcript:Financial Performance:Lumos Pharma ended 2023 with $36.1 million in cash, cash equivalents, and short-term

Futu NewsMar 8 07:51 · Conference Call

Lumos Pharma: Q4 Earnings Insights

Lumos Pharma (NASDAQ:LUMO) reported its Q4 earnings results on Thursday, March 7, 2024 at 04:05 PM.Here's what investors need to know about the announcement.EarningsLumos Pharma missed estimated earni

BenzingaMar 8 05:10

Lumos Pharma Q4 2023 GAAP EPS $(1.170) Misses $(1.150) Estimate, Sales $826.000K Beat $1.750K Estimate

Lumos Pharma (NASDAQ:LUMO) reported quarterly losses of $(1.170) per share which missed the analyst consensus estimate of $(1.150) by 1.74 percent. The company reported quarterly sales of $826.000 th

BenzingaMar 8 05:09

Lumos Pharma 2023 Loss/Shr $4.18 >LUMO

Lumos Pharma 2023 Loss/Shr $4.18 >LUMO

Dow JonesMar 8 05:07

Lumos Pharma: Cash on Hand as of Dec 31 Expected to Support Ops Through 3Q

Lumos Pharma: Cash on Hand as of Dec 31 Expected to Support Ops Through 3Q

Dow JonesMar 8 05:06

Earnings Flash (LUMO) LUMOS PHARMA Reports Q4 Revenue $2.1M

04:02 PM EST, 03/07/2024 (MT Newswires) -- Earnings Flash (LUMO) LUMOS PHARMA Reports Q4 Revenue $2.1M

MT NewswiresMar 8 05:02

Earnings Scheduled For March 7, 2024

Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million. • Stevanato Gr (NYSE:STVN) is likely to report quarte

BenzingaMar 7 17:49

Earnings Preview: Lumos Pharma

Lumos Pharma (NASDAQ:LUMO) is set to give its latest quarterly earnings report on Thursday, 2024-03-07. Here's what investors need to know before the announcement.Analysts estimate that Lumos Pharma w

BenzingaMar 7 02:01

Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024

AUSTIN, Texas, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD)

GlobeNewswireFeb 26 22:00

Lumos Pharma(LUMO.US) Officer Sells US$1,328.02 in Common Stocks

$Lumos Pharma(LUMO.US)$ Officer McKew John C. sold 438 shares of Common Stocks on Feb 6, 2024 at an average price of $3.032 for a total value of $1,328.02.Source: Announcement What is statement of cha

Futu NewsFeb 8 07:05

Lumos Pharma to Participate in Oppenheimer's 34th Annual Healthcare Life Sciences Conference

AUSTIN, Texas, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD), announced

GlobeNewswireFeb 6 05:05

Is Lumos Pharma (NASDAQ:LUMO) In A Good Position To Invest In Growth?

Yahoo FinanceFeb 6 01:24

Press Release: Lumos Pharma Promotes Pisit "Duke" Pitukcheewanont, MD to Chief Medical Officer

Lumos Pharma Promotes Pisit "Duke" Pitukcheewanont, MD to Chief Medical Officer AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical compa

Dow JonesJan 5 05:05

Lumos Pharma Is Maintained at Outperform by Oppenheimer

Lumos Pharma Is Maintained at Outperform by Oppenheimer

Dow JonesDec 11, 2023 23:30